Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Liver Int ; 36(4): 563-71, 2016 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-26503843

RESUMO

BACKGROUND & AIMS: This study was designed to determine the effects of the Dietary Approaches to Stop Hypertension (DASH) diet on weight loss and metabolic status in overweight patients with non-alcoholic fatty liver disease (NAFLD). METHODS: This randomized controlled clinical trial was done among 60 overweight and obese patients with NAFLD. Patients were randomly allocated to consume either the control (n = 30) or the DASH eating pattern (n = 30) for 8 weeks. Both diets were designed to be calorie-restricted. Both diets were consisted of 52-55% carbohydrates, 16-18% proteins and 30% total fats; however, the DASH diet was designed to be rich in fruits, vegetables, whole grains, and low-fat dairy products and low in saturated fats, cholesterol and refined grains. RESULTS: Adherence to the DASH eating pattern, compared to the control diet, weight (P = 0.006), BMI (P = 0.01), alanine aminotransferase (ALT) (P = 0.02), alkalin phosphatase (ALP) (P = 0.001), insulin levels (P = 0.01), homoeostasis model of assessment-estimated insulin resistance (HOMA-IR) (P = 0.01) significantly decreased and quantitative insulin sensitivity check index (QUICKI) (P = 0.004) significantly increased. Compared with the control diet, the DASH diet has resulted in significant reductions in serum triglycerides (P = 0.04) and total-/HDL-cholesterol ratio (P = 0.01). Finally, decreased concentrations of serum high-sensitivity C-reactive protein (hs-CRP) (P = 0.03), malondialdehyde (MDA) (P = 0.04), increased levels of nitric oxide (NO) (P = 0.01) and glutathione (GSH) (P = 0.009) were found in the DASH group compared with the control group. CONCLUSIONS: Consumption of DASH diet for 8 weeks among patients with NAFLD had beneficial effects on weight, BMI, ALT, ALP, triglycerides, markers of insulin metabolism, inflammatory markers, GSH and MDA.


Assuntos
Restrição Calórica , Dieta Redutora , Metabolismo Energético , Hepatopatia Gordurosa não Alcoólica/dietoterapia , Obesidade/dietoterapia , Redução de Peso , Adulto , Idoso , Biomarcadores/sangue , Glicemia/metabolismo , Índice de Massa Corporal , Feminino , Nível de Saúde , Humanos , Mediadores da Inflamação/sangue , Insulina/sangue , Resistência à Insulina , Irã (Geográfico) , Lipídeos/sangue , Masculino , Pessoa de Meia-Idade , Hepatopatia Gordurosa não Alcoólica/sangue , Hepatopatia Gordurosa não Alcoólica/diagnóstico , Hepatopatia Gordurosa não Alcoólica/fisiopatologia , Obesidade/sangue , Obesidade/diagnóstico , Obesidade/fisiopatologia , Cooperação do Paciente , Fatores de Tempo , Resultado do Tratamento
2.
Gastroenterol Hepatol Bed Bench ; 5(4): 197-201, 2012.
Artigo em Inglês | MEDLINE | ID: mdl-24834226

RESUMO

AIM: The aim of this study was to assess the prevalence of celiac disease (CD) in dyspeptic patients. BACKGROUND: Although severe mucosal abnormality with villous atrophy (lesions Marsh III) is the histology gold standard for the diagnosis of CD, non-specific microenteropathy (Marsh I-II) with positive serology is also common Patients with dyspepsia, specific CD antibodies and microenteropathy, could have CD. PATIENTS AND METHODS: From November 2007 to October 2008, 407 randomly chosen patients who underwent diagnostic upper gastrointestinal endoscopy for dyspeptic symptoms (193 male, 214 women; mean age 36.1 years) were studied. Small bowel biopsies were performed in all of them. Histologic characteristics in duodenal biopsy specimens for CD were evaluated according to the modified Marsh Classification. All the patients were also tested for serum total immunoglobulin A and anti-transglutaminase (tTG) antibodies. Those with IgA deficiency were tested for IgG tTG. RESULTS: Duodenal histology showed Marsh I-IIIc lesions in 6.4% cases. 4 patients (0.98%) were IgA deficient and none of them were positive for IgG tTG. Serology showed positive results for tTGA in 8% of the patients and 2.5% of them had abnormal histology (Marsh I-IIIc) compatible with CD. CONCLUSION: The results of this study showed that milder enteropathy (Marsh 0-II) have a low specificity for CD. The prevalence of CD among dyspeptic individuals is significantly (2.5%) higher than in the general population (1%) and CD should be investigated in these patients.

3.
Artigo em Inglês | MEDLINE | ID: mdl-24834153

RESUMO

AIM: We investigated whether the level of IL8 was different in patients with chronic and acute Toxoplasma gondii infection during the pregnancy compared with control group. BACKGROUND: It is well established that T.gondii infection induces a strong cell-mediated immune response. PATIENTS AND METHODS: ELISA was used to determine the level of IL8 in sera of 568 pregnant women. Patients were divided into three groups according to a T.gondii serology. The first group included 202 women with positive IgG titres, the second group was 66 women with IgM and negative IgG T.gondii serology; and the third group comprised the sera of 300 healthy pregnant women with negative T.gondii serology and served as controls. RESULTS: The level of IL8 in group I was within normal range similar to control group. However, the level of IL8 was increased in those pregnant patients with positive IgM T.gondii serology. CONCLUSION: The serum levels of pro-inflammatory cytokines such as IL8 seem to be increased in patients with serological evidence of acute T.gondii infection.

4.
Eur J Gastroenterol Hepatol ; 21(10): 1199-205, 2009 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-19455046

RESUMO

BACKGROUND: End-stage liver disease is a medical problem with high morbidity and mortality. We have investigated the feasibility, safety, and efficacy of using autologous mesenchymal stem cells (MSCs) as a treatment. METHODS: Eight patients (four hepatitis B, one hepatitis C, one alcoholic, and two cryptogenic) with end-stage liver disease having Model for End-Stage Liver Disease score > or =10 were included. Autologous MSCs were taken from iliac crest. Approximately, 30-50 million MSCs were proliferated and injected into peripheral or the portal vein. Liver function and clinical features were evaluated at baseline and 1, 2, 4, 8, and 24 weeks after injection. RESULTS: Treatment was well tolerated by all patients. Liver function improved as verified by the Model for End-Stage Liver Disease score, which decreased from 17.9+/-5.6 to 10.7+/-6.3 (P<0.05) and prothrombin complex from international normalized ratio 1.9+/-0.4 to 1.4+/-0.5 (P<0.05). Serum creatinine decreased from 114+/-35 to 80+/-18 micromol/l (P<0.05). Serum albumin changed from 30+/-5 to 33+/-5 g/l and bilirubin from 46+/-29 to 41+/-31 micromol/l. No adverse effects were noted. CONCLUSION: Our data show that MSCs injection can be used for the treatment of end-stage liver disease with satisfactory tolerability. Furthermore, this treatment may improve clinical indices of liver function in end-stage liver disease.


Assuntos
Cirrose Hepática/terapia , Fígado/fisiopatologia , Transplante de Células-Tronco Mesenquimais/métodos , Adulto , Idoso , Diferenciação Celular , Estudos de Viabilidade , Feminino , Seguimentos , Hepatócitos/citologia , Humanos , Cirrose Hepática/fisiopatologia , Masculino , Transplante de Células-Tronco Mesenquimais/efeitos adversos , Células-Tronco Mesenquimais/citologia , Pessoa de Meia-Idade , Coleta de Tecidos e Órgãos/métodos , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...